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A large number of anti-cancer chemotherapeutics target DNA topoisomerases.  Etoposide 
is a specific topoisomerase II poison which causes reversible double strand DNA breaks. The 
focus of this project is to analyze the repair of DNA damage induced by etoposide..  Double 
strand DNA break repair is mediated by through either non-homologous end joining (NHEJ) or 
homologous recombination.   NHEJ repairs through direct ligation of a double stranded break 
while homologous recombination utilizes a homologous template to recover the wild type 
sequence.   A reporter cassette, RYDR-GFP, has been stably integrated into HeLa cells. This 
reporter contains an ultra-high affinity topoisomerase II cleavage site (RY) placed in the middle 
of a mutant GFP sequence.  Flanking this sequence is a corresponding stretch of wild type GFP 
that is used as template to repair the break and restore gene function yielding GFP positive cells. 
Titrations with etoposide have shown that a logarithmic increase in drug concentration yields a 
corresponding increase in repair through homologous recombination (HR). This result 
demonstrates that topoisomerase II mediated damage is efficiently repaired by the process of HR.  
To examine NHEJ repair, a doxycycline inducible, stably integrated NHEJ HeLa cell reporter 
cassette was also evaluated. The data indicates that repair of topoisomerase II mediated DNA 
damage occurs more efficiently through the HR pathway. Collectively, the data suggests that 
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Chapter One: Introduction 
 Topoisomerase poisons are widely used as anti-cancer chemotherapeutics [2]. 
Topoisomerase II (topoII) is the target for many anti-cancer agents because cancer cells have 
increased mitotic activity, requiring an increase in topoII expression. 
Topoisomerase IIa Mechanism 
The role of topoIIis in relaxation, decatanation, and unwinding DNA during replication and 
cellular division (Figure 1).  A prime example of topoII catalytic activity is during DNA 
replication when the replication fork melts the DNA hydrogen bonds between base pairs.  As a 
result, the DNA preceding the replication fork begins to wind into a highly taut coil called a 
supercoil.  If left alone, this negative supercoiling can be so severe as to fracture the DNA itself, 
thereby creating a genotoxic event [2].  TopoII relaxes the supercoiling. 
 TopoII is homodimer with a Mg
2+
 cation in each dimer. TopoII conformationally exists 
as closed or open clamps dependent upon ATP binding.  ATP binding switches open to closed 
clamp formation.  In each subunit, the Mg
2+
 cation stabilizes, in humans, the tyrosine – 804 
residue in allowing a nucleophillic attack of the 5’ phosphodiester bond [2]. The mechanism is 
repeated on both sides of the double helix.  TopoII is now covalently bound creating a protein-
DNA adduct with a double stranded break (DSB). Transient strand passage translocates the uncut 
strand through the DSB. Within the active site, the dissociated ends are religated.  ATP 
hydrolysis then switches the homodimer to the open conformation.  This mechanism is 
equilibrated and can either increase or decrease the linking number by two.  The isozyme 
topoIIis not mitotically stimulated and is poorly understood, however shares this mechanism 
[2] (Figure 1). 
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Topoisomerase I Mechanism 
 Topoisomerase I (topoI) has importance in mitotic, transcription, and promoter regulation 
[2].  TopoI does not require ATPase activity.  A tyrosine residue performs a nucleophillic attack 
on the 5’ phosphodiester bond, creating a single stranded gap.  TopoI transfers the free 3’ end 
about the intact strand and religates the gap within the catalytic site.  The topoI mechanism is in 

















Figure 1– A. Topoisomerase II Poison; B. 
Topoisomerase II Enzyme Mechanism [2] 
Figure 1 - A. Topoisomerase I  Poison; B. 
Topoisomerase I  Enzyme Mechanism [2] 
 
Figure 2 - TopoII Cleavage 
Complex Repair [4]. 
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Topoisomerase II Poisons 
TopoII poisons such as etoposide (VP16) stabilize enzyme/DNA cleavages and fragment the 
genome (Figure 1).   Many topoII agents are in clinical use and are FDA approved. Therefore, 
it is vital that we understand how topoII breaks are repaired. VP16 itself is a widely used 
chemotherapeutic agent [5].  
Chemotherapy sometimes requires high dosages of topoII agent in order to ensure that 
DNA damage does not undergo repair, as the cleavage complex is a transient and reversible 
event [2].  The stabilized DSB created by topoII poisons increase the half life of the cleavage 
complex.  DNA/topoII complexes are processed by the 26S proteosome, a macromolecular 
structure that degrades ubiquitinated proteins, thus removing the topoII polypeptide portion and 
leaving a DSB (Figure 2) [4].  Recent studies further indicate that the removal of the topoII 
protein can be performed through CtIP and the phosphodiesterases TDP1 and TDP2 [9]. If the 
DNA damage is not efficiently repaired, the cell will undergo apoptosis.  This could possibly 
reduce the amount of agent needed to fight the malignancy.  Information on the repair process 
can lead to new strategies that can inhibit the reversal of topoII mediated DNA damage, 
thereby minimizing patient side effects through the increase of drug efficacy.  
DSB Repair Pathways 
DSBs are common events.  The dissociated ends can reassociate indiscriminately, differing in 
sequence from the wild type. The DSB ultimately can lead to chromosomal translocations [7].  
To circumvent this, cells evolved two known mechanisms to correct the DSB, non-homologous 
end joining (NHEJ) and homologous recombination (HR).     
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NHEJ is the main pathway by which healthy cells repair from DSBs; however this can alter 
gene regulation or expression (Figure 3).  The process involves the direct ligation of a DSB 
without regard to sequence homology or cell cycle [12].  NHEJ is a low fidelity, high mutation 
prone pathway, but repairs DSBs rapidly [12]. Ku, a heterodimer of Ku70 and Ku80, recognizes 
the DSB and initiates the NHEJ repair pathway [12]. The Ku protein attracts DNA-PKcs forming 
a holoenzyme and autophosphorylates itself, possibly providing the energy needed for the 
subsequent blunt ligation.  NHEJ provides genomic stability with a half life of 30 minutes [12]. 
HR is a high fidelity pathway which uses a template donor sequence to reverse a DSB.  HR 
commences upon DNA damage recognition and a cascade of signaling recruits proteins that 
further resect the break to single stranded 3’ ends (Figure 3) [8].  The single stranded ends are 
then coated with single stranded binding proteins, protecting the templates. These unbound ends 
are then wrapped with Rad51, which is associated with BRCA1.  With Rad51 bound, the single 
stranded DNA participates in homology recognition [1]. The Rad51 complex also allows for 
strand exchange.  Subsequent branch migration and nucleotide polymerization from DNA 
polymerase II occur.  The whole complex then resolves itself with an exact copy of the template 
homolog where the DSB occurred.     
Goal 
The goal of this work is to analyze if topoII/DNA damage complexes are repaired through 
either HR or NHEJ.   HR and NHEJ events resulting from poison damage can be quantified 




Figure 3 - NHEJ [11] and HR [7] Pathways.  NHEJ uses the Ku complex to recruit subsequent 
proteins such as DNA-PKcs, ultimately resulting in blunt double strand ligation of the DSB. HR 
is a high fidelity pathway that uses a donor sequence as a template, thus resulting in high fidelity 
DNA retrieval. 
 







Chapter Two: Methods and Materials 
Exposure of DR-GFP HeLa cells to Etoposide and ISce-I 
 Stably integrated DR-GFP (HR) HeLa cells were maintained in 1640 RPMI (Invitrogen) 
supplemented with 10% fetal bovine serum (FBS) (Invitrogen)  in a humidified 37
o
C with 5% 
CO2 incubator. Cells were dispensed into three 12 well plate formats at 200,000 cells per well in 
2 mL 1640 RPMI 10% FBS.   Following 24 hours incubation, six of the twelve wells were 
transfected with 1.2 g pISce-I and 3.6 L Lipofectamine Reagent 2000 (Invitrogen, Carlsbad, 
CA), according to the manufacturer’s instructions for four hours in 1 mL of OPTI-MEM I 
(Invitrogen).  Next, the OPTI-MEM I was aspirated from the transfected wells and dispensed 2 
mL 1640 RMPI 10% FBS, then incubated for 24 hours.  After incubation, the 1640 RPMI from 
all twelve wells were aspirated and 1 mL OPTI-MEM I was added to each well with the desired 
concentration of VP16 from a 20 mM aliquot stock solution (TopoGEN).  The cells were treated 
with VP16 for one hour, then washed with 1 mL 1X PBS, and 2 mL of 1640 RPMI 10% FBS 
was added.  The 12 well plates were incubated for 24 and 72 hours to establish a time course for 
recovery.  At the end of each respective recovery incubation time, 200 L of 0.25% Trypsin-
EDTA (Invitrogen) was added and incubated for 5 minutes.  Next,  200 L of 1640 RPMI 
without FBS was added to neutralize the trypsin and 400 L of the cell suspension was 
dispensed in 400 L 1X PBS in a 5 mL Fluorescence Activated Cell Sorter (FACS) tube 
(FALCON). GFP was read using FACSCalibur and CellQuest software (BD Bioscience, San 
Jose, CA).   
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Screening of RYDR-GFP clones 
  HeLa cells were stably integrated with RY-DRGFP (RY-HR) plasmid (TopoGEN) by 
Alex Fagenson, Dr. Muller laboratory.  Twenty-four hours prior to transfection, the HeLa cells 
were plated at a concentration of 5 x 10
5
 cells per well in a six well plate. The HeLa cells were 
transfected in six-well plates with Lipofectamine 2000 reagent according to manufacturer’s 
instructions. Next, two μg of plasmid DNA, RY-DRGFP #1 and #6 respectively were transfected 
in 1 mL OPTI-MEM I. Four hours following transfection, the media was aspirated and cells were 
grown in 1640 RPMI 10% FBS for twenty four hours. Cells were then washed with 1X PBS, 
trypsinized, and split into 10 cm culture dishes.  Clones were subjected to single colony isolation 
technique while being maintained in media containing puromycin (2 μg/mL) and grown until the 
colonies were visible on the plate (~4 weeks). The 1640 RPMI 10% FBS media was changed 
routinely for both plasmid cultures every four days. Colonies were then picked with a pipette tip 
and placed in 48-well tissue cultured plates. Cells were incubated and forty eight clones of 
plasmid #1 and #6 were maintained in 48 well formats until clone screening was performed. 
 Colonies were selected as single clones and were subcultured and grown up to expand 
the clones.  Healthy cells were plated in six, 12 well plates.  One colony was placed per well in 
two12 well plates.  Approximately 200,000 cells per well were then plated and incubated for 24 
hours with puromycin containing 1640 RPMI.  Following this, 1 g pISce-I with Lipofectamine 
Reagent 2000 was transfected into one of the 12 well plates according to manufacturer’s 
instructions in 1 mL of OPTI-MEM I for five hours.  The media was then aspirated and replaced 
with 2 mL 1640 RPMI 10% FBS and incubated  for 24, 72, and 144 hours.  Using the 
FACSCalibur and CellQuest software, GFP expression was calculated.  The best clone was kept 




 Two 6 well plates were seeded with approximately 100,000 cells per well on top of 
cover slips  in four of the six wells and 2 mL of 1640 RPMI 10% FBS media.  The plates were 
then incubated for 24 hours at 37
o
C, 5% CO2, in a humidified incubator.  The media was then 
aspirated in wells one, three, and four and replaced with 1 mL OPTI-MEM I.  To well one, 2 g 
ISce-I and Lipofectamine Reagent 2000 for the non-inducible RY clone was added according to 
manufacturer’s instructions for four hours, and 2 L of doxycycline for the inducible system was 
incubated until harvesting.  To well three and four, 5 M and 100 M of VP16 respectfully was 
exposed to the cells for one hour.  Following drug treatment, the media was aspirated and 
replaced with 1640 RPMI 10% FBS and incubated for 24 and 48 hours to establish a time course.  
After the desired incubation time, the media was aspirated and the cells were washed with 1X 
PBS.  Using a bent hypodermic needle, the cover slips were carefully removed. A 1.5 M PI 
staining solution stained the cells for thirty minutes in the dark.  The cover slips were then 
washed with 1X PBS.  Using FischerFinest Premium Slides, one drop of emulsion oil was placed 
between the slide and the cover slip.  A KimWipe was used to remove excess oil from around the 
cover slip.  Four drops of clear nail polish was dispensed and a ring was made around, not 
overlapping with, the cover slip and allowed to dry for five minutes.  Then two drops of clear 
nail polish were placed on the edge of the cover slip and using the supplied brush, the nail polish 
was gently made to overlap onto the cover slip.  The slides were dried for five minutes.  The 
slides were then analyzed using a confocal microscope at 20X and 100X power. 
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Analysis of GFP and Methylation in RY-HR Stably Integrated HeLa Cells Using VP16 
 Approximately 1.37 x 10
6
 RY-HR HeLa cells per 100mm plate were incubated in 10 mL 
of 1640 RPMI 10% FBS for a total of 9 plates.  The colonies were incubated at 37
o
C, 5% CO2, 
and in a humidified incubator environment for two days.  Making sure the cells were in heavy 
exponential growth, 0.5 M and 5 M VP16 were added to two of the plates and exposed 
continuously for five days until confluent.  In four plates, 0.5 M, 5 M, 50 M, and 500 M of 
VP16 were exposed for one hour in 2 mL OPTI-MEM I media, then aspirated, and replaced with 
10 mL 1640 RPMI 10% FBS media and incubated for five days.  One plate was left untreated, 
and the last plate was exposed to 5 g of ISce-I for 4 hours with Lipofectamine Reagent 2000 
according to the manufacturer’s instructions in 5 mL OPTI-MEM I.  The media was then 
aspirated and replaced with 1640 RPMI 10% FBS media and incubated for five days until 
confluent.  Using the FACSCalibur and CellQuest software GFP expression was read. 
Trypan Blue Exclusion Assays for Cell Viability 
 RY-HR HeLa cells and NHEJ reporter HeLa cells were plated at approximately 500,000 
cells per well and incubated for 2 days followed by treatment with increasing VP16 
concentrations. Typically, the cells were exposed to VP16 for one hour. The cells were then 
washed and incubated in 1640 RPMI 10% FBS medium for three days.  After the three day 
incubation, 180 L of 0.1% trypan blue dye was aliquot to microcentrifuge tube.  The 
supernatant of each well was saved in a 15 mL conical tube.  The cells were trypsinized with 200 
L of 0.25% Trypsin-EDTA (Invitrogen) and incubated for five minutes under humidified, 37
o
C, 
5% CO2 incubator conditions. To neutralize the trypsin, 200 L of 1640 RPMI was added to the 
trypsinized cells creating a pool of cells, which was then added to the supernatant.  From the cell 
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suspension, 20 L was added to the 180 L of 0.1% trypan blue dye.  From that, 10 L of the 
dyed cells was injected into a hemocytometer slide and viewed under a microscope.  The slide is 
divided into four quadrants and each of the four quadrants was counted and totaled.  A ratio of 
stained versus unstained cells indicates percentage cytotoxicity.  
Analysis of Repair of Topoisomerase I and II DNA Damage by HR and NHEJ Pathways 
Approximately 1x10
6
 cells of both stably integrated RY-HR HeLa cells and inducible, stably 
transfected NHEJ reporter cassette HeLa cells were plated in 11 plates for the RY-HR HeLa line 
and 10 plates for the NHEJ HeLa line.  The cells were incubated for three days in 5% CO2, 37
o
C, 
and humidified conditions.  Following incubation, the cells were observed to be in exponential 
growth.  The plates were exposed to an increase in VP16 concentration, and an increase in 
campothecin (CPT), a topoisomerase I poison for one hour in 2 mL of OPTI-MEM I. A positive 
control and a transfection efficiency control were set up by the transfection of pISce-I and 
pEGFP utilizing Lipofectamine 2000 reagent, according to manufacturer’s instructions.  One 
plate for both lines was left untreated and untransfected as a negative control.  The plates were 
then incubated for 3 days following the drug treatments.  After incubation, the supernatant of the 
plates was transferred to a 15 mL conical tube.  The cells were then trypsinized with 1 mL 0.25% 
Trypsin-EDTA (Invitrogen) for 5 minutes in 37
O
C, 5% CO2, and humidified incubator 
conditions.  The trypsin was then neutralized with 1 mL of 1640 RPMI without FBS, and 1 mL 
of the trypsinized cells was added to 1 mL1X PBS in a 5 mL FACS tube (FALCON).  The cells 




Doxycycline inducible ISce-I expression system 
The inducible reporter system used for the NHEJ and HR HeLa cells lines were stably 
integrated by Dr. Bongyong Lee.  These reporters use a tetracycline induction system to 
transcribe ISce-I endonuclease.    Doxycycline is a semi-synthetic tetracycline derivative.  
Following exposure to doxycycline, the pCMV promoter sequence is exposed allowing for 















Figure 4 – The RYDR-GFP and NHEJ Reporter Constructs.  (A):  RYDR-GFP reporter 
system.  The RY element and the ISce-I loci create DSBs when exposed to a topoII poison or 
ISce-I restriction endonuclease respectively.  The First cassette following a DSB searches for 
homology amongst the second cassette, leading to HR repair of the DSB and GFP expression.  
Before HR repair, cassettes 1 and II are incapable of expressing GFP due to mutations in the first 
cassette and a stop codon in the second cassette. Following HR repair as dictated by the diagram, 
cassette I can express GFP.  (B): The NHEJ reporter system.  The opposing ISce-I restriction cut 
sites allow for direct ligation of the opposing cassettes initiating GFP expression.  The RY 







Chapter Three: Results 
HR analysis following VP16 drug treatments and transfection of ISce-I in HR HeLa cells 
 The treatment of stably integrated HR HeLa cells with VP16 served as an initial and 
essential founding piece of information for the following results (Figure 5).  The positive control 
serves to illustrate the reporter system is working.   The positive control, which includes the 
transfection of ISce-I with no subsequent drug treatment, shows the potential of GFP expression.  
The negative control consists of HR cells, lacking ISce-I transfection and drug treatment, serving 
as a background reading and is ultimately subtracted from the corresponding ISce-I data point.  
Although the anticipated GFP expression for the negative control should be 0%, the 0.1% GFP 
finding is likely due to the nature of the integrated GFP cassettes.   
 The combination of VP16 with the transfection of ISce-I increased the GFP expression 
by 1.3% in the 5 M etoposide range, and steadily declined with higher VP16 concentrations 
thereafter (Figure 5). In addition, GFP expression gradually decreased over time with VP16 
concentrations above 5 M.   However, the remaining increasing VP16 and ISce-I exposures 
were gradually decreased through both time and increasing VP16 concentration.  This is likely 
due to toxicity of the VP16 drug (IC50 = 200 M).   
 Following this data, a plasmid that narrows variability was used.  The RYDR-GFP (RY-
HR) (Figure 4) cassette contains an ultra high affinity 56 base pair purine rich sequence for 
topoII[10].  This high affinity topoII binding site should attract the endogenous topoII and 
direct cleavages in this region 5’ of the ISce-I site in the presence of a drug such as VP16.   As a 
result, the cellular DNA damage repair system should be activated with the HR cassette. The 
results show that HeLa cells are able to repair the VP16 initiated DSB up to 5 M concentration 
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(Figure 6).  Two exposure times of VP16 were allotted for the stably integrated RY-HR HeLa 
cells.  One batch of cells was exposed to VP16 for 5 days.  The second batch was exposed to 
VP16 for 1 hour and then allowed to recover. The positive control is solely a transfection of 
ISce-I plasmid while the negative controls represent GFP expressed in the absence of ISce-I and 
drug treatment.  There is a clear trend with increasing concentration of VP16 treatment in both 
the prolonged and short drug exposure time frames (Figure 6).  During the five day exposure, 
there is an increase of GFP beyond the positive control.  The one hour drug treatments also had 
an increasing trend with increased dosage of VP16 (Figure 6).  The data suggest that the 
presence of the RY element is stimulating HR in the GFP reporter through VP16 drug treatment.  
In this analysis, cells were treated at low to high levels of VP16 for a total of 5 days or with the 
same concentration for 1 hour followed by 5 days of recovery.  In both cases, it is clear that 
VP16 is inducing the formation of WT GFP+ cells at certain concentrations (0.05 – 50 M).  
Higher concentrations were toxic to the cells. As a result of this, we decided that a morphological 






         
 
Figure 5 - HR in VP16 Treated HR HeLa Cells. Stably integrated HR HeLa cells were 
transfected with ISce-I and treated with VP16 for 1 hour as described in the “Materials and 
Methods.”  In a twelve well format, approximately 200,000 cells were seeded per well and 
incubated for 24 hours.  Transfection of ISce-I for 4 hours occurred in the necessary wells for 
four hours.  The cells were then incubated for 24 hours and a 1 hour VP16 drug treatment 
ensued.  A time course for recovery for 72 hours (**p<0.01) was read for GFP expression using 













































Figure 6 - HR in VP16 Treated RY-HR HeLa Cells.  Stably integrated RY-HR HeLa cells 
were seeded at approximately 1.37 x 10
6
cells per plate and incubated for 24 hours.  Following 
incubation, drug treatments lasting for the indicated time (5d = 5 days, 1h = 1 hour) at the stated 
VP16 concentrations.  One hour drug treated cells were washed with 1X PBS, then incubated for 
5 days.  The positive control was transfected with ISce-I for four hours, and recovered for 5 days.  
All cells were harvested simultaneously for GFP analysis via FACS (**p<0.4). Error bars 











Figure 7 - Confocal Microscopy of RY-HR HeLa Cells.  Stably integrated RY-HR HeLa cells 
were seeded over a cover slip and incubated for 24 hours.  Following incubation, 5 M VP16 (A) 
and 100 M VP16 (B) was exposed to the cells for one hour.  The cells were then washed with 
1X PBS and incubated for 2 days.  The cover slips were then removed and stained with a PI 
staining solution for 30 minutes.  The cover slips were washed then adhered onto a slide using 
nail polish.  Confocal microscopy was viewed with fluorescence for GFP and PI.  (A) and (B) 










 Confocal microscopy was performed to examine GFP expressing cells morphologically 
(Figure 7 – 8).  The GFP protein appears to well distributed throughout the cell in the RY-HR 
cultures treated with VP16 for one hour followed by a 48 hour recovery interval.  At 100 M 
VP16 there is an obvious toxic effect.  Confocal analyses were performed on the doxycycline 
inducible NHEJ and HR reporter cells; see “Materials and Methods.”  This experiment was 
preformed to examine any cytological differences between these two reporter systems.  The 
NHEJ reporter yielded cells with GFP distributed throughout the cell (Figure 8).  In contrast, the 
GFP produced as a result of HR in the HR clones appears largely in the nucleus, possibly due to 








Figure 8 - Confocal Microscopy of HR and NHEJ HeLa Cells.  Stably integrated doxycycline 
inducible NHEJ and HR HeLa cell lines were seeded at approximately 200,000 cells per well in 
a 12 well plate with an inherent slide base.  Following 1 day incubation, doxycycline was added 
to the stated wells.  The cells were incubated with the doxycycline for 3 days.  (A) shows the 
uninduced HR HeLa cells at 20X zoom.  (B) shows doxycycline induced HR HeLa cells at 20X 
zoom.  (C) shows doxycycline induced NHEJ reporter system integrated HeLa cells at 20X 










Figure 9 - Cytotoxicity for NHEJ and RY-HR HeLa Cells.  Cytotoxicity percentages were 
calculated for stably integrated inducible NHEJ reporter systems in HeLa cells and stably 
integrated RY-HR HeLa cells.  Both cultures were plated at 500,000 cells per well and incubated 
for 48 hours.  Drug treatments lasted for one hour with both VP16 and CPT (TopoI Poison).  The 
cells were then washed and allotted a recovery interval of 48 hours.  Cytotoxicity percentages 
were calculated using trypan blue exclusion assays. 
 
Stably Integrated, DOX Inducible 
NHEJ Reporter HeLa cells 






Figure 10 - HR and NHEJ After VP16 Treatments  (A). illustrates GFP expression from 
doxycycline inducible stably integrated NHEJ reporter cassettes in HeLa cells.  (B) shows stably 
integrated RY-HR HeLa cells.  Both cell lines were plated at 500,000 cells per well and 
incubated for 48 hours.  Drug treatments lasted for one hour for both VP16 and CPT (TopoI 
poison). For the positive controls; ISce-I transfection lasted for four hours and 3 day exposure for 
the inducible NHEJ system.  The drug treated cells recovered for 3 days and were analyzed for 

































Analysis of Toxicity 
 The results of the trypan blue exclusion assay shows that with increasing concentration of 
VP16, there is an increase in cytotoxicity as expected (Figure 9).  VP16 is a known 
chemotherapeutic and thus should have the high toxicity rating as shown in these results.  CPT, a 
highly specific TopoI poison, shows an increased cytotoxicity amongst the NHEJ reporter 
system with concentrations from 0.5 – 50 M being toxic.  The RY-HR HeLa cells show 
increased resistance to CPT.  The RY-HR toxicity data does show that VP16 is generally less 
cytotoxic than CPT with regard to HR.  
Analysis of Repair of Topoisomerase I and II DNA Damage by HR and NHEJ Pathways 
There are two major DSB repair pathways in animal cells; HR and NHEJ (see 
“Introduction”).  Since we have dedicated reporters for each pathway and given that the drugs 
are highly specific for topoI (CPT) or topoII (VP16) mediated DNA damage, the repair process 
was evaluated in each case (Figure 10).  Figure 10-A, the NHEJ reporter system, shows there is 
an increase in susceptibility in CPT damage and mild reparability in exposure to VP16 with 
dose dependent decrease in GFP. The positive control is noticeably elevated in comparison to 
the remaining samples.  There is a decrease in NHEJ repair with an increase in VP16 
concentration.  Figure 10-B shows the effects of CPT and VP16 on RY-HR HeLa cells.  There 
is an increase in HR with an increase in VP16 concentration and the opposite trend with CPT 
concentration.  In both instances, 50 M of CPT or VP16 caused toxicity in the culture.  The 
data points show that VP16 and CPT HR repair gives a GFP reading close to that of the positive 




Chapter Four: Discussion 
 This project utilizes reporter cassettes to analyze the repair of DNA damage induced by 
topoIIand topoI poisons.  Specific cassettes have been employed that report repair of DSBs by either 
HR or NHEJ (Figure 4).  The first cassette, in the case of RY-HR cultures, contains the topoII hot 
spot for the topoIIpoison and/or an ISce-I restriction endonuclease cut site.  The second 
cassette contains the template sequence to repair the induced DSB in the first cassette.  Without 
drug treatment or transfection GFP is transcribed but not expressed due to mutations in the first 
sequence and a stop codon in the second sequence. The NHEJ pathway is being specifically 
measured using the NHEJ reporter (Figure 4) because the formation of wild type GFP cannot 
proceed by HR due to the lack of a homologous donor sequence. 
The RY-HR GFP reporter systems indicate that with an increase in VP16 concentrations 
to 5 M (Figure 10 - B), there is an increase in HR repair. A dose dependent decrease in the 
NHEJ pathway (Figure 10 – A) in response to VP16 is also observed.  The RY-HR integrated 
cells showed a dose dependent decrease in HR treated with CPT (Figure 10-B).  The DSB 
initiated by VP16 appears to be repaired through the high fidelity, error free HR pathway.   The 
high mitotic activity of cancer cells could make the cell cycle dependent HR repair pathway 
preferential compared to the non-cell cycle dependent NHEJ pathway.  Most healthy cells are in 
the resting G1/G0 phase thus not prone to HR DSB repair. 
The data in Figure 9 define the toxicity profile of VP16. The highly specific topoI 
poison CPT had a higher toxicity than the VP16.  HR may well be the preferred DSB repair 
pathway because the cancer cells are constantly dividing and HR is cell cycle specific.  
Moreover, HR proteins are associated with specific cell cycle checkpoints, whereas NHEJ is 
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not [14].  Due to the high mitotic levels of most cancer cells, HR should be a prominent 
pathway for break repair.  However, not all cancer cell types follow the HR pathway 
preferentially.  For example, both normal and malignant urothelial cells upregulate the NHEJ 
pathway, while HR is more dominant in cervical cancer cells [15].  The data and literature 
suggest that DSB repair pathways are highly variable and may well be dependent on tumor 
tissue location. Most importantly, since healthy cells preferentially use NHEJ to repair DSBs, a 
selective agent for HR proteins could sensitize cells to anti-cancer treatments while leaving 
healthy cells relatively unharmed.  One report demonstrated that NHEJ targeting sensitized 
tumor cells and caused normal cell damage [16].  The targeting of HR could lessen the 
malevolent impact of chemotherapy on healthy cells, and thereby target cancer cells selectively.  
Future work for this project includes analyzing, through the same reporter constructs, 
the effects of VP16 and CPT drug treatments on cell lines known for specific repair pathway 
upregulation.  For instance, B cell lines are highly associated with NHEJ pathways.  In addition, 
topoII analysis can be preformed based on the two pathways.  TopoII has been found to be a 
causative enzyme of secondary malignancies in patients served topoII poisons.  Finally, 
knockout or over expression of specific proteins upregulated in HR such as BRCA1 can be 
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